Article thumbnail

Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D

By Selidji T. Agnandji, Rolf Fendel, Michaël Mestré, Michel Janssens, Johan Vekemans, Jana Held, Ferdinand Gnansounou, Sonja Haertle, Isabel von Glasenapp, Sunny Oyakhirome, Ludovic Mewono, Philippe Moris, Marc Lievens, Marie-Ange Demoitie, Patrice M. Dubois, Tonya Villafana, Erik Jongert, Aurelie Olivier, Joe Cohen, Meral Esen, Peter G. Kremsner, Bertrand Lell and Benjamin Mordmüller
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1997). A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria.
  2. (2009). A randomized trial assessing the safety and immunogenicity
  3. (1982). Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells.
  4. (2000). Antigenspecific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized.
  5. (1990). CD4+ cytolytic T cell clone confers protection against murine malaria.
  6. (1988). CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites.
  7. (2002). Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response.
  8. (2006). CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
  9. (2006). Dendritic cell immaturity during infancy restricts the capacity to express vaccine-specific T-cell memory.
  10. (2009). Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine.
  11. (2003). Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant.
  12. (2007). Duration of humoral immunity to common viral and vaccine antigens.
  13. (2005). Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial.
  14. (2006). Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naı ¨ve and malaria-exposed individuals.
  15. (1993). Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages.
  16. (2008). Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
  17. (2001). Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
  18. (2004). Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial.
  19. (2009). Five-year safety and immunogenicity of GlaxoSmithKline’s candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
  20. (2009). Follicular helper T cells as cognate regulators of B cell immunity.
  21. (1987). g Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites.
  22. (2001). Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th1 function.
  23. (2001). ICOS is critical for CD40-mediated antibody class switching.
  24. (2008). IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells.
  25. (2010). Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: A phase II, randomized, open, controlled study.
  26. (2008). Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen.
  27. (1998). Long term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
  28. (1998). Long-lived plasma cells: a mechanism for maintaining persistent antibody production.
  29. (1996). Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection.
  30. (2008). Maintenance of the plasma cell pool is independent of memory B cells.
  31. (1994). Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction.
  32. (1980). Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection.
  33. (1990). Peptideprimed CD4+ cells and malaria sporozoites.
  34. (2009). Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.
  35. (2006). Preclinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
  36. (2007). Predicting memory: a prospective readout for malaria vaccines?
  37. (2003). Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ Tc e l l s producing IFN-gamma.
  38. (1997). Radbruch A
  39. (2009). RTS,S Vaccine Evaluation Group. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
  40. (2007). Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique.
  41. (1995). Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
  42. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more.
  43. (1997). The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response.
  44. (2008). The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.
  45. (1993). The role of CD4+ T cells in immunity to malaria sporozoites.
  46. (2009). The who, how and where of antigen presentation to B cells.
  47. (2002). Traggiai E, Lanzavecchia A
  48. (2006). Understanding and making use of human memory B cells.